Curia Global, Inc.

Curia Global, Inc. operates as a contract research, development, and manufacturing organization. The company discovers and develops an active pharmaceutical ingredient (API); and develops a messenger RNA (mRNA) solution to streamline the development and delivery of mRNA-based products. It offers custom API manufacturing, fermentation, finished dosage form, high potency, lipid nanoparticle, rare/orphan, stability and release testing, sterile fill finish, APIs and intermediates catalog, and fine chemicals catalog. The company offers analytical testing services, batch release and stability lot testing, extractables and leachable, method development and validation, package and device testing, and solid-state chemistry lab testing services. It also offers intellectual property litigation support, intellectual property services, regulatory support, quality assurance, and sterile university consultative services. The company offers products and services from research and development through commercial manufacturing to pharmaceutical and biopharmaceutical customers. The company was formerly known as AMRI and changed its name to Curia Global, Inc. in July 2021. Curia Global, Inc. was founded in 1991 and is headquartered in Albany, New York.